Literature DB >> 26945010

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

B H O'Neil, A J Scott, W W Ma, S J Cohen, D L Aisner, A R Menter, M A Tejani, J K Cho, J Granfortuna, A L Coveler, O O Olowokure, J C Baranda, M Cusnir, P Phillip, J Boles, R Nazemzadeh, M Rarick, D J Cohen, J Radford, L Fehrenbacher, R Bajaj, V Bathini, P Fanta, J Berlin, A J McRee, R Maguire, F Wilhelm, M Maniar, A Jimeno, C L Gomes, W A Messersmith.   

Abstract

Entities:  

Year:  2016        PMID： 26945010      PMCID： PMC6795379          DOI： 10.1093/annonc/mdw095

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  9 in total

Review 1.  Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.

Authors:  Eric S Christenson; Elizabeth Jaffee; Nilofer S Azad
Journal:  Lancet Oncol       Date:  2020-03       Impact factor: 41.316

Review 2.  Small molecule inhibitors in pancreatic cancer.

Authors:  Jufeng Sun; Cecilia C Russell; Christopher J Scarlett; Adam McCluskey
Journal:  RSC Med Chem       Date:  2020-01-24

3.  Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer.

Authors:  Emma Kurz; Carolina Alcantara Hirsch; Tanner Dalton; Sorin Alberto Shadaloey; Alireza Khodadadi-Jamayran; George Miller; Sumedha Pareek; Hajar Rajaei; Chirayu Mohindroo; Seyda Baydogan; An Ngo-Huang; Nathan Parker; Matthew H G Katz; Maria Petzel; Emily Vucic; Florencia McAllister; Keri Schadler; Rafael Winograd; Dafna Bar-Sagi
Journal:  Cancer Cell       Date:  2022-06-02       Impact factor: 38.585

4.  An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.

Authors:  Chen-Lei Wen; Ke Huang; Lu-Lu Jiang; Xiong-Xiong Lu; Yu-Ting Dai; Min-Min Shi; Xiao-Mei Tang; Qing-Bing Wang; Xiao-Dan Zhang; Peng-Hui Wang; Hui-Ti Li; Xiao-Xue Ruan; Li-Wen Wang; Xin-Jing Wang; Qian Wang; Wei Lu; Xiao-Qiang Xiang; Xun Sun; Yan-Hui Xu; Lu-Hua Lai; Qian Zhan; Hong-Wei Li; Cheng-Hong Peng; Jing Chen; Jin-Yan Huang; De-Yong Ye; Sai-Juan Chen; Zhu Chen; Min Li; Yuan Fang; Bai-Yong Shen; Lu Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-29       Impact factor: 11.205

Review 5.  Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.

Authors:  Hai-Feng Hu; Zeng Ye; Yi Qin; Xiao-Wu Xu; Xian-Jun Yu; Qi-Feng Zhuo; Shun-Rong Ji
Journal:  Acta Pharmacol Sin       Date:  2021-02-11       Impact factor: 7.169

Review 6.  From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers.

Authors:  Ioannis D Kyrochristos; Georgios K Glantzounis; Demosthenes E Ziogas; Ioannis Gizas; Dimitrios Schizas; Efstathios G Lykoudis; Evangelos Felekouras; Anastasios Machairas; Christos Katsios; Theodoros Liakakos; William C Cho; Dimitrios H Roukos
Journal:  Int J Mol Sci       Date:  2017-01-18       Impact factor: 5.923

7.  Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.

Authors:  Peter Dietrich; Kim Freese; Abdo Mahli; Wolfgang Erwin Thasler; Claus Hellerbrand; Anja Katrin Bosserhoff
Journal:  Oncotarget       Date:  2017-12-11

8.  Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.

Authors:  Li Xu; Yuanrun Zhu; Jinjin Shao; Min Chen; Hao Yan; Guanqun Li; Yi Zhu; Zhifei Xu; Bo Yang; Peihua Luo; Qiaojun He
Journal:  Br J Cancer       Date:  2017-03-07       Impact factor: 7.640

9.  The anticipating value of PLK1 for diagnosis, progress and prognosis and its prospective mechanism in gastric cancer: a comprehensive investigation based on high-throughput data and immunohistochemical validation.

Authors:  Peng Lin; Dan-Dan Xiong; Yi-Wu Dang; Hong Yang; Yun He; Dong-Yue Wen; Xin-Gan Qin; Gang Chen
Journal:  Oncotarget       Date:  2017-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.